Please login to the form below

Not currently logged in
Email:
Password:

Kadcyla

This page shows the latest Kadcyla news and features for those working in and with pharma, biotech and healthcare.

EMA fast-tracks review of AZ/Daiichi Sankyo’s HER2 drug

EMA fast-tracks review of AZ/Daiichi Sankyo’s HER2 drug

The FDA approval and EMA application include data from the DESTINY-Breast01 trial in patients who had previously been treated with Herceptin, Perjeta or Kadcyla. ... Analysts have predicated that AZ/Daiichi’s drug could overtake Kadcyla and become a

Latest news

More from news
Approximately 17 fully matching, plus 49 partially matching documents found.

Latest Intelligence

  • Cortellis Drugs to Watch in 2020 report Cortellis Drugs to Watch in 2020 report

    Kadcyla, the only other anti-HER2 ADC in this market, is a direct competitor and differentiation versus this established drug will be key.

  • 20 for 2020 – Five pharma companies to watch 20 for 2020 – Five pharma companies to watch

    The key difference between DS-8201 and Kadcyla is that Daiichi’s drug has a more potent chemotherapy payload that also gets into cells more readily. ... If those plans go well, estimates are that sales of DS-8201 could eclipse Kadcyla and enter

  • Positive disruption in business intelligence Positive disruption in business intelligence

    Take the recent recommendation by NICE, the UK’s drug-spending policymaker, of Kadcyla, the breast cancer treatment launched by Roche. ... In December 2016, NICE issued draft guidance indicating Kadcyla was too expensive for routine funding on the NHS.

  • Back to the future Back to the future

    and Kadcyla.

  • Pharma deals during August 2013 Pharma deals during August 2013

    The technology enables the development of “armed” antibodies to deliver potent cell-killing agents to cancer cells, sparing nearby healthy cells. Proof-of-concept has been established with Genentech's Kadcyla

More from intelligence
Approximately 0 fully matching, plus 6 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Graphite Digital

Graphite is a digital agency which partners with globally respected healthcare organisations to create powerful digital experiences....

Latest intelligence

Kulveer Singh
Surviving cancer: a new era for patients
Now more than ever, a shift in perspective is needed...
Crisis? No problem!
Issues planning & management for pharma spokespeople, by Andrew Smith...
Are patient recruitment and retention rates rising or falling?
First up, the good news. Over the past seven years, clinical trial recruitment rates have been on the rise....

Infographics